[go: up one dir, main page]

NO990912L - Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav - Google Patents

Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav

Info

Publication number
NO990912L
NO990912L NO990912A NO990912A NO990912L NO 990912 L NO990912 L NO 990912L NO 990912 A NO990912 A NO 990912A NO 990912 A NO990912 A NO 990912A NO 990912 L NO990912 L NO 990912L
Authority
NO
Norway
Prior art keywords
antagonist
rar
therapeutic combinations
rxr agonists
antagonists
Prior art date
Application number
NO990912A
Other languages
English (en)
Other versions
NO990912D0 (no
Inventor
Pierre Chambon
Hinrich Gronemeyer
Peter R Reczek
Jacek Ostrowski
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Pasteur
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Pasteur, Bristol Myers Squibb Co filed Critical Inst Nat Sante Rech Med
Publication of NO990912D0 publication Critical patent/NO990912D0/no
Publication of NO990912L publication Critical patent/NO990912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
NO990912A 1996-08-28 1999-02-25 Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav NO990912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28
PCT/US1997/015155 WO1998008546A2 (en) 1996-08-28 1997-08-28 Therapeutic combinations of rar antagonists and rxr agonists and use thereof

Publications (2)

Publication Number Publication Date
NO990912D0 NO990912D0 (no) 1999-02-25
NO990912L true NO990912L (no) 1999-04-27

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990912A NO990912L (no) 1996-08-28 1999-02-25 Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav

Country Status (11)

Country Link
US (2) US6130230A (no)
EP (1) EP0928200B1 (no)
JP (1) JP2001500486A (no)
AT (1) ATE236654T1 (no)
AU (1) AU731060B2 (no)
CA (1) CA2263817A1 (no)
DE (1) DE69720745T2 (no)
ES (1) ES2196361T3 (no)
IL (1) IL128723A0 (no)
NO (1) NO990912L (no)
WO (1) WO1998008546A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344653A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
JP2003526677A (ja) * 2000-03-14 2003-09-09 ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ 骨形成に影響を与える組成物および方法
AU4866201A (en) * 2000-04-13 2001-10-30 Pierre Chambon Compositions and methods for use in modulating immune system function
AU6503901A (en) * 2000-05-26 2001-12-11 Univ Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
EP1478384A2 (en) * 2001-06-11 2004-11-24 Ludwig Institute For Cancer Research Method for increasing the survival of dopamine secreting cells
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
EP2329817A1 (en) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer
ES2759584T3 (es) 2011-06-24 2020-05-11 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias
EP2814950A1 (en) 2012-02-13 2014-12-24 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9963439B2 (en) 2013-08-20 2018-05-08 University Of Washington Through Its Center For Commercialization Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
MX2018015352A (es) * 2016-06-10 2019-03-28 Io Therapeutics Inc Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
JP2020526551A (ja) 2017-07-13 2020-08-31 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せた免疫調節性レチノイド及びレキシノイド化合物
SG11202001479RA (en) 2017-08-31 2020-03-30 Io Therapeutics Inc Rar selective agonists in combination with immune modulators for cancer immunotherapy
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508507A (ja) 1991-03-18 1994-09-29 ザ　ソールク　インスチチュート　フォア　バイオロジカル　スタディズ 受容体認識配列組成物およびこれを用いた分析法
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0659045A4 (en) * 1993-05-18 1997-02-26 Inst Nat Sante Rech Med MOUSE GENETICALLY GENERATED AND COMPRISING MODIFICATIONS IN GENES ENCODING RETINOIC ACID RECEPTOR PROTEINS.
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
CA2210248A1 (en) 1995-01-13 1996-07-18 Ronald M. Evans Allosteric control of nuclear hormone receptors
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
WO1998029120A1 (en) 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
EP0963199A1 (en) 1996-12-31 1999-12-15 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Also Published As

Publication number Publication date
WO1998008546A2 (en) 1998-03-05
WO1998008546A3 (en) 1998-04-23
JP2001500486A (ja) 2001-01-16
AU731060B2 (en) 2001-03-22
CA2263817A1 (en) 1998-03-05
US6130230A (en) 2000-10-10
US6653322B1 (en) 2003-11-25
DE69720745T2 (de) 2004-02-26
NO990912D0 (no) 1999-02-25
EP0928200B1 (en) 2003-04-09
IL128723A0 (en) 2000-01-31
EP0928200A2 (en) 1999-07-14
WO1998008546A8 (en) 2001-04-19
ES2196361T3 (es) 2003-12-16
DE69720745D1 (de) 2003-05-15
AU4167497A (en) 1998-03-19
ATE236654T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
NO990912L (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
BR0008847A (pt) Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
YU2603A (sh) Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija
DK0415613T3 (da) Anvendelse af sertralin til behandling af præmatur ejakulation
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
IT1269185B (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
DK0768083T3 (da) Anvendelse af sertralin til at behandle patienter med post myocardisk infarkt
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
PA8435601A1 (es) Composiciones farmaceuticas y metodos de tratamiento de desordenes compulsivos usando inhibidores de naaladasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application